When will Cellectis report earnings and why does it matter for ALCLS.PA stock?

Cellectis reports earnings after markets close on 12 Mar 2026. The report matters because clinical updates, guidance, and partner news can change investor expectations quickly and move ALCLS.PA stock, given its biotech valuation profile and recent trading volume.

What is Meyka AI's short-term and 12-month ALCLS.PA forecast?

Meyka AI's forecast model projects **€3.30** monthly, **€4.06** quarterly, and **€5.60** in 12 months. Compared to the current **€3.47**, the 12-month forecast implies about **61.39%** upside. Forecasts are model-based and not guarantees.

What are the main valuation metrics to watch for ALCLS.PA stock at earnings?

Key metrics: EPS **-0.28**, P/S **3.64**, P/B **3.78**, current ratio **1.49**, and debt-to-equity **0.92**. Investors should watch guidance that affects revenue growth and the R&D burn rate, which directly influence valuation multiples for ALCLS.PA stock.

How should traders approach intraday moves in ALCLS.PA stock ahead of earnings?

Traders should monitor volume relative to the **304,082.00** average, price action around **€3.52** (50-day) and **€2.89** (200-day), and news flow about trials. Use tight risk controls because biotech earnings are binary and can widen intraday spreads for ALCLS.PA stock.

EU Stocks

ALCLS.PA Cellectis EURONEXT €3.47 intraday 10 Mar 2026: earnings loom

ByHuzaifa Zahoor March 10, 2026

ALCLS.PA stock jumps 9.81% intraday to €3.47 as traders price in Cellectis S.A.’s upcoming earnings on 12 Mar 2026. The move follows renewed interest in the company’s allogeneic CAR-T pipeline and a mixed sell-side view. Volume sits at 158,359.00 versus an average 304,082.00, signalling selective buying. With EPS at -0.28 and a negative PE of -11.64, investors should focus on clinical updates and cash runway data in the report. This earnings spotlight lays out what could shift the tradeable outlook for ALCLS.PA stock.